Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AGIO Agios Pharmaceuticals	$38.80 +1.6%	$36.82	$23.42 ▼ $62.58	$2.25B	0.8	966,978 shs	722,567 shs
DNLI Denali Therapeutics	$15.49 +1.7%	$14.31	$10.57 ▼ $33.33	$2.26B	1.36	1.74 million shs	2.74 million shs
GLPG Galapagos	$32.00 +0.3%	$30.66	$22.36 ▼ $33.86	N/A	0.1	362,193 shs	161,129 shs
ORKA Oruka Therapeutics	$15.44 +4.4%	$13.56	$5.49 ▼ $52.32	$578.06M	-0.35	142,141 shs	152,697 shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AGIO Agios Pharmaceuticals	+1.57%	+4.84%	-4.34%	+30.20%	-17.62%
DNLI Denali Therapeutics	+1.71%	+5.37%	+7.05%	+15.42%	-38.04%
GLPG Galapagos	+0.25%	-1.45%	-3.88%	+11.38%	+26.88%
ORKA Oruka Therapeutics	+4.39%	+0.46%	+6.19%	+41.00%	+1,543,999,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AGIO Agios Pharmaceuticals	4.3779 of 5 stars	3.4	2.0	4.3	2.9	0.8	1.9
DNLI Denali Therapeutics	4.2019 of 5 stars	3.6	1.0	4.7	3.0	3.3	0.0
GLPG Galapagos	0.1291 of 5 stars	0.7	2.0	0.0	0.6	0.0	0.6
ORKA Oruka Therapeutics	2.3266 of 5 stars	3.6	0.0	0.0	1.0	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AGIO Agios Pharmaceuticals	2.75	Moderate Buy	$56.33	45.19% Upside
DNLI Denali Therapeutics	3.12	Buy	$33.62	117.01% Upside
GLPG Galapagos	1.38	Strong Sell	$25.33	-20.83% Downside
ORKA Oruka Therapeutics	3.20	Buy	$40.38	161.50% Upside

Current Analyst Ratings Breakdown

Latest ORKA, DNLI, AGIO, and GLPG Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/18/2025	DNLI Denali Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$33.00 ➝ $30.00
8/18/2025	ORKA Oruka Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$45.00
8/12/2025	ORKA Oruka Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$40.00
8/5/2025	GLPG Galapagos	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Sell
7/28/2025	AGIO Agios Pharmaceuticals	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Outperform ➝ Sector Outperform	$71.00 ➝ $65.00
7/28/2025	DNLI Denali Therapeutics	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
7/23/2025	ORKA Oruka Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$45.00
7/22/2025	AGIO Agios Pharmaceuticals	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$52.00 ➝ $51.00
7/21/2025	ORKA Oruka Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$40.00

(Data available from 8/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AGIO Agios Pharmaceuticals	$36.50M	61.76	N/A	N/A	$23.57 per share	1.65
DNLI Denali Therapeutics	$330.53M	6.85	N/A	N/A	$7.02 per share	2.21
GLPG Galapagos	$298.31M	N/A	$0.73 per share	44.07	$47.57 per share	N/A
ORKA Oruka Therapeutics	N/A	N/A	N/A	N/A	$9.10 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AGIO Agios Pharmaceuticals	$673.72M	$11.00	3.53	N/A	N/A	1,590.42%	-3.49%	-3.23%	10/30/2025 (Estimated)
DNLI Denali Therapeutics	-$422.77M	-$2.80	N/A	N/A	N/A	N/A	-40.79%	-36.39%	11/5/2025 (Estimated)
GLPG Galapagos	$80.16M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	10/22/2025 (Estimated)
ORKA Oruka Therapeutics	-$83.72M	-$2.81	N/A	N/A	N/A	N/A	-26.26%	-24.16%	N/A

Latest ORKA, DNLI, AGIO, and GLPG Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2025	Q2 2025	DNLI Denali Therapeutics	-$0.74	-$0.72	+$0.02	-$0.72	$5.64 million	N/A
8/11/2025	Q1 2025	ORKA Oruka Therapeutics	-$0.48	-$0.46	+$0.02	-$0.46	N/A	N/A
7/31/2025	Q2 2025	AGIO Agios Pharmaceuticals	-$1.74	-$1.93	-$0.19	-$1.93	$9.46 million	$12.50 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AGIO Agios Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
DNLI Denali Therapeutics	N/A	N/A	N/A	N/A	N/A
GLPG Galapagos	N/A	N/A	N/A	N/A	N/A
ORKA Oruka Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AGIO Agios Pharmaceuticals	N/A	14.48	14.04
DNLI Denali Therapeutics	0.01	10.27	10.27
GLPG Galapagos	N/A	8.08	7.99
ORKA Oruka Therapeutics	N/A	27.42	27.42

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AGIO Agios Pharmaceuticals	N/A
DNLI Denali Therapeutics	92.92%
GLPG Galapagos	32.46%
ORKA Oruka Therapeutics	56.44%

Insider Ownership

Company	Insider Ownership
AGIO Agios Pharmaceuticals	4.30%
DNLI Denali Therapeutics	12.50%
GLPG Galapagos	2.91%
ORKA Oruka Therapeutics	24.69%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AGIO Agios Pharmaceuticals	390	58.10 million	55.60 million	Optionable
DNLI Denali Therapeutics	430	146.21 million	127.94 million	Optionable
GLPG Galapagos	1,310	N/A	N/A	Optionable
ORKA Oruka Therapeutics	N/A	37.45 million	28.20 million	N/A

ORKA, DNLI, AGIO, and GLPG Headlines

Recent News About These Companies

Q3 EPS Forecast for Oruka Therapeutics Decreased by Analyst

August 22 at 7:21 AM | marketbeat.com

HC Wainwright Issues Negative Estimate for ORKA Earnings

August 22 at 2:29 AM | americanbankingnews.com

Oruka Therapeutics initiated with a Buy at Clear Street

August 21 at 3:41 AM | msn.com

Oruka Therapeutics (NASDAQ:ORKA) Earns Buy Rating from HC Wainwright

August 20 at 8:24 AM | marketbeat.com

HC Wainwright Reiterates Buy Rating for Oruka Therapeutics (NASDAQ:ORKA)

August 20 at 2:19 AM | americanbankingnews.com

Oruka Therapeutics (ORKA) Receives a Buy from H.C. Wainwright

August 19, 2025 | theglobeandmail.com

Oruka Therapeutics (NASDAQ:ORKA) Rating Lowered to "Sell" at Wall Street Zen

August 18, 2025 | americanbankingnews.com

Wedbush Forecasts Reduced Earnings for Oruka Therapeutics

August 17, 2025 | marketbeat.com

Oruka Therapeutics (NASDAQ:ORKA) Downgraded by Wall Street Zen to "Sell"

August 17, 2025 | marketbeat.com

Q3 EPS Estimate for Oruka Therapeutics Lowered by Analyst

August 17, 2025 | americanbankingnews.com

Q3 EPS Forecast for Oruka Therapeutics Reduced by Analyst

August 16, 2025 | marketbeat.com

Oruka Therapeutics (NASDAQ:ORKA) Is In A Good Position To Deliver On Growth Plans

August 15, 2025 | finance.yahoo.com

Oruka Therapeutics (NASDAQ:ORKA) Trading 7.1% Higher - Here's Why

August 15, 2025 | marketbeat.com

Leerink Partnrs Has Pessimistic View of ORKA Q3 Earnings

August 15, 2025 | americanbankingnews.com

Wedbush Reiterates "Outperform" Rating for Oruka Therapeutics (NASDAQ:ORKA)

August 14, 2025 | americanbankingnews.com

Oruka Therapeutics' (ORKA) "Outperform" Rating Reiterated at Wedbush

August 13, 2025 | marketbeat.com

Oruka Therapeutics (NASDAQ:ORKA) Releases Quarterly Earnings Results, Beats Expectations By $0.02 EPS

August 12, 2025 | marketbeat.com

Oruka Therapeutics reports Q2 EPS (46c), consensus (43c)

August 12, 2025 | msn.com

Oruka Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

August 11, 2025 | globenewswire.com

Oruka Therapeutics, Inc. (NASDAQ:ORKA) Receives Average Recommendation of "Buy" from Analysts

August 10, 2025 | marketbeat.com

Oruka Therapeutics (NASDAQ:ORKA) Trading Down 9.4% - Here's Why

August 7, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ORKA, DNLI, AGIO, and GLPG Company Descriptions

Agios Pharmaceuticals NASDAQ:AGIO

$38.80 +0.60 (+1.57%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$38.81 +0.01 (+0.02%)

As of 08/22/2025 05:51 PM Eastern

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Denali Therapeutics NASDAQ:DNLI

$15.49 +0.26 (+1.71%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$15.56 +0.07 (+0.48%)

As of 08/22/2025 07:34 PM Eastern

Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

Galapagos NASDAQ:GLPG

$32.00 +0.08 (+0.25%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$32.55 +0.55 (+1.72%)

As of 08/22/2025 05:06 PM Eastern

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.

Oruka Therapeutics NASDAQ:ORKA

$15.44 +0.65 (+4.39%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$15.41 -0.03 (-0.19%)

As of 08/22/2025 04:10 PM Eastern

Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time